Optimal timing of surgery after neoadjuvant chemoradiotherapy in rectal cancer: A retrospective analysis
European Journal of Surgical Oncology · 2025
DOI: 10.1016/j.ejso.2025.109702 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Mojtaba Ahmadinejad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, School of Medicine, Alborz University of Medical Science, Karaj, Iran. Electronic address: md.m.ahmadinejad@gmail.com. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy, Adjuvant, Proctectomy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Determining the optimal interval between neoadjuvant chemoradiotherapy (NCRT) and surgery in patients with locally advanced rectal cancer (LARC) remains crucial for improving treatment outcomes. Extending the interval may increase rates of pathological complete response (pCR), potentially enhancing survival and reducing recurrence. METHODS: This retrospective cohort study included 226 patients with LARC who underwent NCRT followed by surgery. ROC analysis was used to establish the optimal interval between NCRT and surgery for achieving pCR, and multivariate logistic regression assessed independent predictors of pCR. Spline regression further analyzed the relationship between surgery timing and the probability of pCR. RESULTS: ROC analysis identified 10.5 weeks as the optimal interval, showing increased pCR rates within this period. Multivariate analysis confirmed that surgery interval (OR = 2.603, P = 0.045) significantly predicted pCR. Both ROC and spline regression indicated that a 9-11-week interval maximizes pCR probability. Notably, the comparison of postoperative complications between groups with surgery intervals ≤10 weeks and >10 weeks showed no statistically significant differences (P = 0.518). CONCLUSION: An interval of 9-11 weeks between NCRT and surgery optimizes pCR rates without increasing postoperative risks. This timeframe may serve as a favorable window for surgical intervention to enhance outcomes in rectal cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, School of Medicine, Alborz University of Medical Science, Karaj, Iran. Electronic address: md.m.ahmadinejad@gmail.com.
- Radiation Oncology, Independent Practice, Karaj, Iran. Electronic address: parviziarash@gmail.com.
- Department of Surgery, School of Medicine, Alborz University of Medical Science, Karaj, Iran. Electronic address: S.sheikhi@abzums.ac.ir.
- Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: fatemeheghbal7@gmail.com.
- General Practitioner, Independent Practice, Karaj, Iran. Electronic address: Susan.navabian@yahoo.com.
- Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: Faranak.chaboki97@gmail.com.
Zitieren
APA
Ahmadinejad, M., Parvizi, A., Sheikhi, S., Eghbal, F., Navabian, S., Chaboki, F., Bahri, M. H., Bozorgmehr, R., Bagherpour, J. Z., & Ziaie, S. (2025). Optimal timing of surgery after neoadjuvant chemoradiotherapy in rectal cancer: A retrospective analysis. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.109702
Vancouver
Ahmadinejad M, Parvizi A, Sheikhi S, Eghbal F, Navabian S, Chaboki F, et al. Optimal timing of surgery after neoadjuvant chemoradiotherapy in rectal cancer: A retrospective analysis. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.109702
BibTeX
@article{Ahmadinejad2025,
author = {Ahmadinejad, Mojtaba and Parvizi, Arash and Sheikhi, Saman and Eghbal, Fatemeh and Navabian, Susan and Chaboki, Faranak and Bahri, Mohammad Hadi and Bozorgmehr, Ramin and Bagherpour, Javad Zebarjadi and Ziaie, Shirin},
title = {Optimal timing of surgery after neoadjuvant chemoradiotherapy in rectal cancer: A retrospective analysis},
journal = {European Journal of Surgical Oncology},
year = {2025},
doi = {10.1016/j.ejso.2025.109702}
}
EUVIMED